- The FDA has accepted Cara Therapeutics Inc's (NASDAQ: CARA) and its partner's Vifor Pharma GNHAF marketing application for Korsuva (difelikefalin) solution for injection for pruritus (or itch) in hemodialysis patients.
- Under priority review status, the target action date is August 23.
- The agency also stated that currently, it is not planning to hold an advisory committee for the application.
- If approved, Korsuva injection would be the first therapy for the treatment of pruritus in hemodialysis patients.
- Price Action: CARA shares are up 8.40% at $18.09 in the premarket trading on the last check Monday.
CARACara Therapeutics Inc
$5.432.07%
Edge Rankings
Momentum
87.38
Growth
-
Quality
-
Value
27.56
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in